More than 100 Republican members of Congress have filed an amicus brief urging the Supreme Court to reinstate in-person dispensing requirements for mifepristone, the chemical abortion drug at the center of an escalating legal fight between Louisiana and the federal government. The brief, led by Senate Majority Leader John Thune, House Speaker Mike Johnson, Sen. Bill Cassidy, and Rep. Chris Smith, argues that loosened federal rules have enabled coercion, stripped away medical safeguards, and put women and girls at serious risk, Fox News Digital reported.
The filing lands as the Supreme Court weighs emergency petitions from mifepristone manufacturers Danco Laboratories and GenBioPro, which want the justices to block a Fifth Circuit ruling that sided with Louisiana and restored the in-person prescribing requirement while litigation continues.
At stake is whether the FDA overstepped when it removed the in-person dispensing requirement from its Risk Evaluation and Mitigation Strategy, known as REMS, and allowed abortion pills to be prescribed via telehealth and shipped through the mail. The Republican lawmakers say the answer is yes, and that the consequences are already showing up in emergency rooms and in cases of alleged coercion against women who never consented to taking the drug.
The amicus brief makes a pointed case that mail-order access to mifepristone "increases the risk of coercion." Lawmakers point to the case of Rosalie Markezich, a plaintiff who says her boyfriend ordered the drug from a California doctor and forced her to take it. The brief states:
"Had she visited a doctor in person, her boyfriend would never have been able to obtain the drugs he made [her] take."
That case is not the only one cited. The brief also references an alleged incident in Louisiana involving a mother and her teenage daughter, though full case details were not provided in the filing as described. The broader argument is straightforward: when a powerful drug can be ordered online and delivered to a doorstep with no in-person medical visit, there is no doctor present to screen for abuse, coercion, or dangerous medical conditions like ectopic pregnancy.
Rep. Smith, a New Jersey Republican, has argued that more than one in 10 women experience complications from the drug, including infection or hemorrhaging. Eliminating the face-to-face visit, lawmakers contend, makes it harder to catch those risks before they become emergencies.
Sen. Cassidy, the Louisiana Republican who helped lead the brief framed the issue as one of immediate patient safety and urged the high court to act:
"Chemical abortion drugs kill innocent children and put mothers' lives at risk. Safeguards protecting against coercion, such as the in-person dispensing requirement, must be reinstated immediately. The Fifth Circuit got this right, and I urge the Supreme Court to affirm that decision."
Senate Majority Leader Thune struck a similar tone, pressing for the Department of Health and Human Services to conduct a fresh review of the drugs. His statement made clear that the Republican conference sees this as a matter of regulatory accountability, not just social policy:
"There are legitimate concerns about these drugs putting women and girls at significant risk. I urge the Supreme Court to reinstate the safety guardrails that were in place before the Biden administration while the Department of Health and Human Services reviews these drugs."
That reference to the Biden administration is significant. The lawmakers' brief argues that the prior administration's FDA weakened the REMS framework in ways that conflicted with both sound medical practice and existing federal law, specifically the Comstock Act, which prohibits mailing items "designed, adapted, or intended for producing abortion."
The case reached this point after Louisiana sued the FDA, arguing that expanded mail-order access to mifepristone effectively allowed out-of-state prescribers to circumvent the state's abortion ban. The Fifth Circuit agreed, finding that Louisiana had demonstrated irreparable harm. As the Washington Examiner reported, the appeals court's opinion stated that "the regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law."
That ruling restored the in-person dispensing requirement. But the legal fight intensified over the weekend when Danco Laboratories and GenBioPro filed emergency appeals, warning the Supreme Court that the Fifth Circuit's order had caused "immediate confusion and upheaval" in time-sensitive medical decisions.
The hidden Supreme Court has been at the center of fierce partisan battles in recent years, with Democrats making aggressive moves to challenge the institution's authority whenever rulings cut against progressive priorities.
Justice Samuel Alito responded by temporarily staying the Fifth Circuit's order, restoring mail-order access to mifepristone while the full court considers the emergency petitions. The New York Post reported that Alito's pause runs until May 11, giving the justices time to decide whether to let the lower court's ruling take effect or keep it on hold as the case proceeds.
It is worth noting that this is a temporary procedural step, not a ruling on the merits. The underlying legal questions about FDA authority, the Comstock Act, and state sovereignty remain very much alive.
The National Review noted a tension within the broader conservative coalition on this issue. Family Research Council president Tony Perkins observed: "You have Republican states that are challenging a Republican administration over this because their laws are being undermined." That dynamic, red states pushing the federal government to enforce restrictions the executive branch has been slower to reimpose, reveals the complexity of the post-Dobbs landscape.
After the Supreme Court returned abortion policy to the states in 2022, states like Louisiana moved to restrict or ban the procedure within their borders. But those laws mean little if the FDA's mail-order framework allows pills to flow across state lines unchecked. That is precisely the argument Louisiana and its congressional allies are making.
The amicus brief from more than 100 lawmakers adds significant political weight to that legal argument. With the Senate majority leader and the House speaker both signing on, the filing signals that congressional Republicans are not content to let this fight play out in the courts alone. They want the Supreme Court to know where the elected branches stand.
Chief Justice John Roberts has insisted the Court is not a political body, but the institution finds itself once again at the intersection of regulatory power, federalism, and one of the most charged social issues in American life.
The Supreme Court must now decide whether to let the Fifth Circuit's in-person requirement take effect or extend the temporary hold while the full case proceeds. A decision on the emergency petitions could come as soon as mid-May.
For the Republican lawmakers who signed the brief, the ask is simple: restore the safeguards that existed before the Biden-era FDA loosened the rules. They argue that those changes were made without adequate safety data, in defiance of the Comstock Act, and with no regard for state laws enacted after Dobbs.
Meanwhile, some Democrats have responded to the broader abortion-pill fight by renewing calls to restructure the Supreme Court itself. Sen. Cory Booker has pledged a Court overhaul if Democrats retake Congress, a reminder that for the left, the preferred remedy when courts enforce the law is to change the courts.
The manufacturers' argument boils down to convenience and access. The lawmakers' argument boils down to safety and consent. The question of which value the legal system should prioritize is now squarely before the nine justices.
Some members of the left have gone so far as to label the Supreme Court "illegitimate" when it reaches conclusions they dislike. That tells you something about which side trusts the constitutional process, and which side only trusts outcomes.
When a woman can be coerced into taking a powerful drug ordered online by someone else, and the federal government's answer is to make that drug even easier to get without a doctor in the room, the policy has failed the people it claims to protect. More than 100 lawmakers just told the Supreme Court as much. The question is whether the Court is listening.
